Where next for Cancer Immunotherapy? - The Scientist


	The article you are attempting to read is Premium content which is only available to our online subscribers.

Subscribing to The Scientist is easy and inexpensive.

And you can choose from many options. Try us out with an online day pass starting at only $4.95. Or, get it all with unlimited online access to The Scientist Archive and door-to-door delivery of our monthly print magazine.


	The Scientist also offers site licenses to institutions and organizations. When your librarian adds The Scientist to the library's collection, you can get unlimited online access through your place of work or study. Recommend The Scientist today



Where next for Cancer Immunotherapy? Despite its obvious scientific appeal, immunotherapy as an approach to cancer has yet to live up to expectations. Initial attempts at using cytokines to stimulate anticancer T cells, or deploying toxin-conjugated monoclonal antibodies as "magic bullets," were never quite successful despite having attracted considerable attention.